Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 7/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | NAAA | Q02083 | 1/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.54 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.52 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23442089 | 1.00 | CASP2 (0.59) | CASP2FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL23443051 | 1.00 | CASP2 (0.59) | CASP2FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL23442081 | 1.00 | CASP2 (0.59) | CASP2FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL23442079 | 1.00 | CASP2 (0.59) | CASP2FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL23442074 | 1.00 | CASP2 (0.59) | CASP2FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL23443050 | 1.00 | CASP2 (0.59) | CASP2FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL23442084 | 1.00 | CASP2 (0.59) | CASP2FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL23443054 | 1.00 | CASP2 (0.59) | CASP2FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL23443048 | 1.00 | CASP2 (0.59) | CASP2FAAHMEN1KMT2AMAPK1 | |
| SCHEMBL23442090 | 1.00 | CASP2 (0.59) | CASP2FAAHMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NOVARTIS AG (CH) | 2023-05-25 | — | — | US | disclosed |
| WO-2023091985-A1 | COMPOUNDS TARGETING PMP22 FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE | DTX PHARMA, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2021108640-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | DTX PHARMA, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021108662-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | DTX PHARMA, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NSUN2, NSUN3, POLM | CASP2 3292/4885FAAH 3897/4885MEN1 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.